Showing 1581-1590 of 1735 results for "".
- TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for Glaucoma Drug Candidate TC-002https://modernod.com/news/tearclear-announces-positive-topline-results-from-clear-phase-3-study-for-the-treatment-of-glaucoma-with-tc-002-latanoprost-ophthalmic-solution-0005/2481165/TearClear announced that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR phase 3 pivotal trial. With these results, TearClear plans to file a new drug application (NDA) with the FDA in
- Visus Therapeutics Acquires Assets of ViewPoint Therapeuticshttps://modernod.com/news/visus-therapeutics-acquires-assets-of-viewpoint-therapeutics/2481124/Visus Therapeutics announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics. Financial terms of the deal were not disclosed. Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation
- Cimerli, First Biosimilar Interchangeable to Lucentis, Set to Launch in the UShttps://modernod.com/news/coherus-to-launch-cimerli-ranibizumab-eqrn-in-the-us/2481103/Coherus BioSciences announced the commercial availability, beginning October 3, 2022, of Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all approved indications. Cimerli was approved by the FDA in August 2022, having met FDA&rs
- SamaCare’s Prior Authorization Management Platform Available on the ModMed EMRhttps://modernod.com/news/samacares-prior-authorization-management-platform-available-on-the-modmed-emr/2481065/Retina and multi-specialty ophthalmology practices will now be able to synchronize data and share documents between the ModMed all-in-one ophthalmology solution and SamaCare’s prior authorization management platform, according to a SamaCare news release. The interface su
- Lucentis Biosimilar Ranivisio Receives Marketing Authorization from European Commissionhttps://modernod.com/news/european-commission-grants-marketing-authorization-for-ranivisio-for-amd/2481057/Teva Pharmaceuticals announced that it has received marketing authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar of Lucentis. The authorization includes all five indications for which Lucentis is authorized in adults.
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- SAV-IOL to Showcase IOL Technology at ESCRS 2022https://modernod.com/news/sav-iol-to-showcase-new-iol-technology-at-escrs-2022/2481038/After nearly 3 years of virtual congresses and canceled tradeshows worldwide, SAV-IOL announced it will be exhibiting at this year’s ESCRS event in Milan, Italy, September 16-19 at stand B14 at MiCo Convention Centre. SAV-IOL invites all participants to come check out their E
- Show Organizers Announce Reimagined Floor Plan for Vision Expo East 2023https://modernod.com/news/show-organizers-announce-reimagined-floor-plan-for-vision-expo-east-2023/2481037/The Vision Council and RX, co-organizers of Vision Expo, shared plans for a reimagined show floor layout that will debut at Vision Expo East 2023, taking place March 16–19 at the Javits Center in New York City. The new layout will feature all of Vision Expo’s Show Fl
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these